ArticleScientific reports2026
A nomogram for risk stratification of protein-energy malnutrition in pediatric cancer patients: development and internal validation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
To develop and internally validate a nomogram for predicting the risk of protein-energy malnutrition (PEM) in pediatric cancer patients and to evaluate its clinical utility. A total of 375 pediatric cancer patients admitted to a tertiary hospital in Xinjiang (January-May 2025) were enrolled. Nutritional status was assessed using the WHO BMI-for-age Z-score. Candidate variables (P < 0.01 in univariate analysis) were entered into the least absolute shrinkage and selection operator (LASSO) model, and multivariate logistic regression was applied to construct the prediction model. Model performance was assessed using the area under the receiver operating characteristic curve (AUC), calibration plots with the Hosmer-Lemeshow test, and decision curve analysis (DCA). Six readily obtainable variables were retained in the final model. Protective factors included being an only child (OR = 0.278), time since diagnosis of 0-6 months (OR = 0.264) or > 12 months (OR = 0.351), caregiver education of high school or above (OR = 0.406), and household per-capita income ≥ 1,000 yuan (OR = 0.255). Rural residence (OR = 2.643) and ≥ 6 chemotherapy cycles (OR = 2.259) were risk factors for PEM. The nomogram demonstrated robust discrimination in both the modeling (AUC = 0.823, 95% CI: 0.767-0.868) and validation (AUC = 0.779, 95% CI: 0.685-0.859) cohorts. Calibration curves showed close agreement between predicted and observed probabilities, and Hosmer-Lemeshow tests indicated good fit (all P > 0.05). DCA confirmed meaningful net clinical benefit across a wide range of threshold probabilities. The nomogram provides an interpretable and clinically practical tool for early identification of PEM risk in pediatric cancer patients, supporting targeted nutritional screening and timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.